Investor
ARCH Venture Management, LLC
CIK 0001274403 · filed 2026-05-15 · SEC filing
13F book
$677.1M
Positions
10
1 new · 0 sold
Largest name
18.2%
Maze Therapeutics, Inc. · MAZE
Est. mark
$14.5M
Price effect on 9 names still held. Flow $10.9M.
| Name | Ticker | Shares | Value | Weight | Est. mark | Change |
|---|---|---|---|---|---|---|
| Maze Therapeutics, Inc. | MAZE | 4.12M | $123M | 18.2% | −$47.7M | Held |
| Rapport Therapeutics, Inc. | RAPP | 3.73M | $116.7M | 17.2% | $3.54M | Held |
| Vir Biotechnology, Inc. | VIR | 12.9M | $115.7M | 17.1% | $37.8M | Held |
| Erasca, Inc. | ERAS | 7.09M | $114.7M | 16.9% | $88.4M | Cut$73.6M |
| Beam Therapeutics Inc. | BEAM | 4.54M | $108.2M | 16.0% | −$17.7M | Held |
| Lyell Immunopharma, Inc. | LYEL | 3.25M | $65.1M | 9.6% | −$29.6M | Added−$19.8M |
| Generate Biomedicines, Inc. | GENB | 1.94M | $24.3M | 3.6% | — | New |
| 10x Genomics, Inc. | TXG | 217.8K | $4.62M | 0.7% | $1.07M | Cut−$7.4M |
| Gossamer Bio, Inc. | GOSS | 8.06M | $2.65M | 0.4% | −$22.3M | Held |
| Q32 Bio Inc. | QTTB | 320.5K | $2.06M | 0.3% | $993.5K | Held |
Positions as of Q1 2026. 13F filings arrive up to 45 days after quarter-end and omit shorts. Values are quarter-end marks, as filed. Estimated mark is the price effect on shares still held — not realized P&L or investment advice.